Preferred shares and fair-value liabilities

Hong Kong IPO disclosure precedents · 233 companies, 234 items

redeemable / convertible preferred shares or other instruments with redemption rights, fair-value losses, conversion on listing

2026-06-29Prospectus
EACON Group Co., Ltd易控智驾科技股份有限公司07687.HK

During the Track Record Period, our fair value changes on financial liabilities at FVTPL amounted to RMB33.5 million, RMB66.1 million, and nil in 2023, 2024, 2025, respectively.

Financial Information · p. 219

Our fair value changes on financial liabilities at FVTPL increased by RMB32.6 million, or 97.3% from RMB33.5 million in 2023 to RMB66.1 million in 2024, primarily attributable to the fair value changes in our shares with preferred rights classified as financial liabilities, driven by adjustments in valuation assumptions related to our improving business outlook, higher projected performances, and increased probability of a liquidity event such as an initial public offering.

Financial Information · p. 225

In 2024, our financial position improved from net liabilities of RMB812.5 million as of December 31, 2023 to net assets of RMB260.0 million as of December 31, 2024, primarily attributable to the conversion of substantially all historical rounds of shares with preferred rights into ordinary shares of RMB1,415.7 million and additional capital contributions from shareholders, partially offset by a loss and total comprehensive expense of RMB390.6 million.

Summary · p. 7
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-29Application Proof

We recorded fair value losses of convertible redeemable preferred shares of RMB73.0 million, RMB76.2 million and RMB147.8 million in 2023, 2024 and 2025, respectively, resulting from the increase in fair value of convertible redeemable preferred shares.

Financial Information · p. 227

On May 30, 2025, we reached an agreement with the holders of the convertible redeemable preferred shares that we repurchased 3,454,613 Series D Preferred Shares at a total consideration of USD24,000,000 in June 2025 and the holders would not exercise the redemption rights to request us to repurchase their outstanding Preferred Shares on or before December 31, 2026.

Financial Information · p. 244

We do not expect to recognize any further fair value gain or loss on convertible redeemable preferred shares in the future upon [REDACTED].

Financial Information · p. 244
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-26Application Proof
Shanghai Union Technology Corporation上海联泰科技股份有限公司

As of December 31, 2023, 2024, 2025 and April 30, 2026, we had redemption liabilities of RMB515.9 million, RMB588.4 million, RMB580.5 million and RMB618.0 million, respectively.

Financial Information · p. 208

During the Track Record Period, we recorded interest on redemption liabilities of RMB42.2 million, RMB42.5 million and RMB41.8 million in 2023, 2024 and 2025, respectively.

Financial Information · p. 190

While we recorded net losses during the Track Record Period primarily due to interest on redemption liabilities, our business remains sustainable and is supported by substantial growth momentum.

Business · p. 128
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-25Application Proof
Hangzhou Lygo Technology Co., Ltd.杭州灵卡科技股份有限公司

We recorded losses from fair value changes of financial liabilities through profit or loss of RMB83.2 million, RMB12.3 million and RMB165.3 million in 2023, 2024 and 2025, respectively, primarily attributable to changes in the valuation of our Company.

Financial Information · p. 212

Our fair value loss on financial liabilities represents changes in the carrying amount of our equity share with redemption rights issued to pre-[REDACTED] investors.

Financial Information · p. 212

We do not expect to record any further fair value losses of financial liabilities at fair value through profit or loss upon the [REDACTED] as such issuance of equity shares with redemption rights will be re-designated and reclassified from liabilities to equity as a result of the termination of the redemption rights upon the [REDACTED].

Financial Information · p. 206
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-25Application Proof
WinHealth International Holding Group Company Limited维健国际控股集团有限公司

Our fair value change in financial instruments issued to investors were RMB10.3 million, RMB47.4 million and RMB238.2 million, respectively, for the years ended December 31, 2023, 2024 and 2025.

Financial Information · p. 235

The fair values of the convertible redeemable preferred shares and convertible loans measured at fair value through profit or loss are determined using the valuation technique of hybrid approach, combining the discounted cash flow method, the backsolve method and the option-pricing method.

Financial Information · p. 223

These preferred shares will be reclassified from liabilities to equity as a result of the conversion into ordinary shares upon the [REDACTED]. Subsequently, we do not expect to record any further fair value change in financial instruments issued to investors.

Financial Information · p. 238
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-24Application Proof
Zixun Technology (Fujian) Co., Ltd.紫讯技术(福建)股份有限公司

Our redemption liabilities amounted to RMB509.2 million, RMB597.4 million, RMB714.0 million and RMB714.1 million as of December 31, 2023, 2024, and 2025 and April 30, 2026, respectively.

Financial Information · p. 203

Upon the [REDACTED], the preferential rights attached to these shares will be automatically terminated, and the corresponding redemption liabilities will be derecognized and reclassified as equity.

Financial Information · p. 203

We recorded changes in the carrying amount of the redemption liabilities of RMB124.7 million, RMB88.2 million and RMB177.9 million in 2023, 2024 and 2025.

Financial Information · p. 188
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-24Application Proof
EpimAb Biotherapeutics Inc.岸迈生物科技有限公司

Our fair value losses on convertible redeemable preferred shares amounted to RMB232.7 million, in 2024, as compared to fair value losses on convertible redeemable preferred shares of RMB25.7 million in 2025, respectively.

Financial Information · p. 240

Convertible redeemable preferred shares amounted to RMB2,747.1 million and RMB2,772.8 million as of December 31, 2024 and 2025, respectively.

Financial Information · p. 250

Our fair value losses on convertible redeemable preferred shares decreased from RMB232.7 million in 2024 to RMB25.7 million in 2025, reflecting changes in the fair value of our Preferred Shares.

Financial Information · p. 242
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-24Application Proof
JIIOV Technology (Tianjin) Co., Ltd.极豪科技(天津)股份有限公司

We recorded changes in the carrying amount of redemption liabilities of negative RMB19.0 million, negative RMB18.1 million and negative RMB28.7 million in 2023, 2024 and 2025, respectively.

Financial Information · p. 190

Such financial liabilities are measured at the higher of: (i) the investment amount paid by the investors plus an annual simple interest rate of 8% for the period commencing from the investment payment date to the redemption settlement date; and (ii) the fair value of the Company corresponding to the proportion of registered capital put by the investors.

Financial Information · p. 190

The redemption liabilities will be reclassified from liabilities to equity upon [REDACTED].

Financial Information · p. 190
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-22Application Proof
Taihe Music Group太合音乐集团

During the Track Record Period, we recognized fair value changes of convertible redeemable preferred shares of RMB55.0 million, RMB35.4 million and RMB14.0 million in 2023, 2024 and 2025, respectively, representing losses recorded in our consolidated statements of profit or loss.

Financial Information · p. 202

The convertible redeemable preferred shares will be automatically converted into Ordinary Shares immediately before the closing of the [REDACTED], and accordingly no further fair value changes will be recognized after the [REDACTED].

Financial Information · p. 202

Our convertible redeemable preferred shares amounted to RMB1,574.9 million, RMB1,634.1 million and RMB1,611.7 million as of December 31, 2023, 2024 and 2025, respectively.

Financial Information · p. 215
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-22Prospectus
Zhejiang Laifual Drive Co., Ltd.浙江来福谐波传动股份有限公司03952.HK

We had redemption liabilities of RMB917.3 million, RMB1,062.4 million, RMB1,207.4 million and RMB818.1 million as of December 31, 2023, 2024 and 2025 and April 30, 2026, respectively.

Financial Information · p. 242

We recognized our obligation to pay cash to those investors with redemption right as financial liabilities, because not all triggering events in the relevant agreements are within our control.

Financial Information · p. 242

We had change in the carrying amount of redemption liabilities of RMB145.1 million, RMB145.1 million and RMB145.1 million in 2023, 2024 and 2025, respectively.

Financial Information · p. 226
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-18Prospectus
Baige Online Digital Technology Co., Ltd.白鸽在线(厦门)数字科技股份有限公司02672.HK

our puttable shares liabilities will be re-designated from liabilities to equity as a result of the automatic conversion into ordinary shares and our position of net current liabilities would turn into net current assets upon Listing.

Financial Information · p. 306

Upon the execution of shareholders’ agreement following series B financing, the agreed return rate payable by the Company for previously issued contingently redeemable preferred shares upon exercise of repurchase right was reduced, we therefore recognized a gain on modification of puttable shares liabilities in 2023.

Financial Information · p. 295
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-18Application Proof
DataStory Artificial Intelligence Technology Co., Ltd.数说故事人工智能科技股份有限公司

We define adjusted net profit/(loss) as loss for the year/period adjusted by adding back (i) [REDACTED], which are expenses incurred in relation to this [REDACTED], (ii) share-based payment expenses, which are primarily non-cash in nature, and (iii) interest on redemption right liabilities, which is related to the preferential rights granted to certain Pre-[REDACTED] Investors and is non-cash in nature, and the redemption right liabilities will be reclassified to equity of our Company upon the completion of the [REDACTED].

Summary · p. 8

Interest on redemption right liabilities relates to the preferential rights granted to certain Pre-[REDACTED] Investors and is non-cash in nature, and the redemption right liabilities will be re-classified to equity of our Company upon the completion of the [REDACTED].

Financial Information · p. 204
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-18Prospectus
Alebund Pharmaceuticals (Jiangsu) Limited礼邦医药(江苏)股份有限公司09637.HK

Our redemption liabilities on ordinary shares decreased from RMB1,712.6 million as of December 31, 2024 to nil as of December 31, 2025, primarily due to the irrevocable termination of the general redemption rights granted to the shareholders and the redemption liabilities on ordinary shares were credited to other reserve.

Financial Information · p. 259
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-17Application Proof
Juhui Food Technology Co., Ltd聚慧食品科技有限公司

Our other gains/losses, net primarily consisted of fair value gains/(losses) on financial assets at fair value through profit or loss (FVTPL), fair value gains/(losses) on financial liabilities at FVTPL, gains/(losses) on disposal of property, plant and equipment, and donations.

Financial Information · p. 173

Our net other gains decreased by 85.3% from RMB12.8 million in 2024 to RMB1.9 million in 2025, primarily attributable to repurchase of preferred shares in 2025.

Financial Information · p. 179

We recorded net gains of RMB12.8 million in 2024 as compared to net losses of RMB7.5 million in 2023, primarily attributable to repurchase of preferred shares in 2024.

Financial Information · p. 181
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-17Application Proof
Beijing Rongxin Datainfo Science and Technology Co., Ltd.北京融信数联科技股份有限公司

Our redemption liabilities arise from the redemption right granted to our Pre-[REDACTED] Investors, which amounted to RMB214.2 million, RMB214.4 million and RMB218.3 million as at December 31, 2023, 2024 and 2025, respectively.

Financial Information · p. 232

We recorded fair value changes of our redemption liabilities of RMB3.2 million, RMB0.3 million and RMB3.9 million in FY2023, FY2024 and FY2025, respectively, arising from the redemption rights granted to our Pre-[REDACTED] Investors.

Financial Information · p. 214

Under this agreement, all the Special Rights are terminated effective on the date of signature.

Financial Information · p. 200
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-17Application Proof
BANU INTERNATIONAL HOLDING LTD巴奴国际控股有限公司

As of December 31, 2023, 2024, 2025 and April 30, 2026, our redemption liabilities were RMB327.1 million, RMB301.5 million, RMB320.1 million and RMB326.3 million, respectively.

Financial Information · p. 229

In 2023, 2024 and 2025, changes in carrying amount of redemption liabilities were RMB23.7 million, RMB21.1 million and RMB18.6 million, respectively, accounting for 1.1%, 0.9% and 0.7% of our total revenue in the same years, respectively.

Financial Information · p. 214

Under this conversion feature, all preferred rights of the holders of preferred shares will be terminated and the preferred shares will be automatically converted into ordinary shares upon the completion of the [REDACTED].

Financial Information · p. 229
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-16Application Proof
BEIJING RC TECH CO., LTD.北京云中融信网络科技股份有限公司

Our redemption liabilities primarily relate to our obligations arising from certain redemption rights and liquidation preferences granted to the holders of preferred rights in connection with our historical equity financing activities.

Financial Information · p. 207

During the Track Record Period, we recognized finance costs arising from redemption liabilities of approximately RMB32.1 million, RMB32.2 million and RMB12.6 million for the years ended December 31, 2023, 2024 and 2025, respectively.

Financial Information · p. 207

In May 2025, we entered into a preferred rights termination agreement with the preferred shareholders, pursuant to which the agreed redemption was terminated, and the redemption liabilities were derecognized after entering into such agreement.

Financial Information · p. 208
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-16Application Proof

In 2023, we recorded a fair value gain of RMB361.9 million, primarily due to a decrease in the fair value of the convertible preferred shares.

Financial Information · p. 204

In 2024 and 2025, we recorded fair value losses of RMB29.1 million and RMB67.4 million, respectively, primarily due to an increase in the fair value of such instruments.

Financial Information · p. 204

The Series A Preferred Shares will be automatically converted into ordinary shares upon completion of the [REDACTED], and we do not expect to record further gains or losses in relation to valuation changes in such instruments after the [REDACTED].

Financial Information · p. 204
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-15Application Proof
TRIAPEX LABORATORIES CO., LTD.江苏鼎泰药物研究(集团)股份有限公司

From 2021 to 2023, we entered into certain financing agreements with several investors, pursuant to which we issued our share capital, facilitated the transfer of shares by certain original shareholders, and granted investors certain special rights.

Financial Information · p. 228

We recognized redemption liabilities of RMB2,418.0 million, RMB2,623.7 million and RMB2,823.0 million as of December 31, 2023, 2024 and 2025, respectively.

Summary · p. 9

Our changes in carrying amount of redemption liabilities amounted to RMB195.9 million, RMB205.7 million and RMB206.1 million, in 2023, 2024 and 2025, respectively.

Financial Information · p. 211
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-15Prospectus
Shaanxi Micot Pharmaceutical Technology Co., Ltd.陕西麦科奥特医药科技股份有限公司02335.HK

As of December 31, 2024, December 31, 2025 and April 30, 2026, our redemption liabilities, which were unsecured and unguaranteed, amounted to nil, RMB1,159 million and RMB1,202 million, respectively.

Financial Information · p. 267

Our redemption liabilities primarily represent our obligation to purchase our equity instruments, which is conditional on the exercise by certain investors of the right to require their investments to be redeemed.

Financial Information · p. 267
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us